Poziotinib - Hanmi Pharmaceutical

Drug Profile

Poziotinib - Hanmi Pharmaceutical

Alternative Names: HM-781-36B; NOV-120101

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Chonnam National University Hospital; Chungnam National University; Hanmi Pharmaceutical; Konkuk University Medical Center; Korean Association for the Study of Targeted Therapys; Kosin University Gospel Hospital; Kyungpook National University Medical School; Spectrum Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; Yonsei University Health System
  • Class Anilinouracils; Antineoplastics; Piperidines; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 03 May 2018 Spectrum Pharmaceuticals in-licenses patents related to methods of use of Poziotinib from University of Texas M. D. Anderson Cancer Center
  • 03 May 2018 Spectrum Pharmaceuticals plans a basket trial in exon 20 mutations in Solid tumours
  • 28 Apr 2018 No recent reports of development identified for clinical-Phase-Unknown development in Colorectal-cancer in South Korea (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top